Status:
RECRUITING
An Observation Study on the Identification of Prescription Patterns of Lodient Tab(Telmisartan/S-amlodipine)
Lead Sponsor:
Hanlim Pharm. Co., Ltd.
Conditions:
Hypertension
Eligibility:
All Genders
19+ years
Brief Summary
This study identify prescription patterns of Lodient Tab and evaluate the changes of the hypertension symptoms (BP pressure) who are first prescribed and taking Lodient Tab.
Detailed Description
This study aims to observe changes in symptoms according to the treatment effect of hypertension for 6 months after Lodient Tab prescription.
Eligibility Criteria
Inclusion
- Adults over 19 years of age
- A person diagnosed with hypertension
- A person who has been first prescribed Lodient Tab within the past 4 months as of the IRB approval date or is scheduled to be prescribed Lodient Tab
- A person who voluntarily agreed in writing to this study
Exclusion
- Pregnant women or nursing mothers
- Persons subject to prohibition according to the permission of the Lodient Tab
- Patients who in the judgement of the investigator, were inappropriate to participate in the study
Key Trial Info
Start Date :
November 11 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2025
Estimated Enrollment :
4000 Patients enrolled
Trial Details
Trial ID
NCT06214832
Start Date
November 11 2021
End Date
August 30 2025
Last Update
January 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul song clinic
Seoul, South Korea